Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
allergan
2
×
biotech
boston blog main
2
×
clinical trials
crispr
deals
editas medicine
life sciences
national blog main
san francisco blog main
akouos
alnylam pharmaceuticals
alzheimer's disease
amag pharmaceuticals
amunix
anirvan ghosh
astrazeneca
biogen
bluerock therapeutics
boston
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
cerovene
covid-19
cynthia collins
deerfield management
detroit blog main
detroit top stories
durvalumab
europe blog main
europe top stories
fda
forty seven
fred hutch
gene editing
general atlantic
What
medicines
2
×
abbvie
acquisitions
alliance
announced
bio
biotech
ceo
collabs
covid
daniel
deal
editas
editing
exits
experimental
gene
genetic
gilead
gilead’s
help
introduce
ipo
month
o’day
pact
partnership
plans
pruning
research
returning
rights
roundup
sciences
terminated
transformative
treatment
years
Language
unset
Current search:
allergan
×
medicines
×
" boston blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
